Refining Alzheimer's disease biological diagnosis with plasma biomarkers: Resolving p‐tau217 “gray zone” with p‐tau181 integration

TL;DR

Researchers found that combining two blood biomarkers improves Alzheimer's diagnosis, especially for cases with unclear results.

Contribution

The study introduces a sequential plasma biomarker strategy to resolve diagnostic uncertainty in Alzheimer's disease.

Findings

Plasma p-tau217 showed the highest accuracy for detecting AD pathology.

A two-cutoff strategy for p-tau217 improved diagnostic reliability.

p-tau181 resolved 77.4% of intermediate p-tau217 cases.

Abstract

Blood‐based biomarkers offer a less invasive and more scalable alternative to cerebrospinal fluid (CSF) analysis and amyloid‐positron emission tomography (PET) for the biological diagnosis of Alzheimer's disease (AD). Among blood‐based biomarkers (BBMs), plasma phosphorylated tau217 (p‐tau217) has shown the highest accuracy, although intermediate (“gray zone”) values remain challenging to interpret.

In this study, 401 individuals across the Alzheimer's Disease (AD) continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and AD dementia) underwent clinical and biomarker assessment. Plasma p‐tau217, p‐tau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured. Core1 status was defined through CSF or amyloid‐PET.

Plasma p‐tau217 demonstrated the strongest discrimination of Core1 positivity (area under the curve [AUC] = 0.95) and showed the steepest increase with disease progression. A two‐cutoff strategy improved diagnostic accuracy (94%), though 18% of patients fell into the gray zone. Within this subgroup, p‐tau181 was the only predictor of Core1 status and correctly reclassified 77.4% of indeterminate cases.

These findings support a sequential plasma biomarkers approach for reliable AD detection.

Plasma phosphorylated tau217 (p‐tau217) showed the highest accuracy for detecting Alzheimer's disease (AD) pathology.A two‐cutoff strategy for p‐tau217 improved diagnostic reliability.About 18% of patients displayed intermediate p‐tau217 “gray zone” values.p‐tau181 was the only biomarker that resolved p‐tau217 gray zone cases.Sequential use of p‐tau217 and p‐tau181 enhanced classification accuracy.

Plasma phosphorylated tau217 (p‐tau217) showed the highest accuracy for detecting Alzheimer's disease (AD) pathology.

A two‐cutoff strategy for p‐tau217 improved diagnostic reliability.

About 18% of patients displayed intermediate p‐tau217 “gray zone” values.

p‐tau181 was the only biomarker that resolved p‐tau217 gray zone cases.

Sequential use of p‐tau217 and p‐tau181 enhanced classification accuracy.

Figures